Pfizer Inc. and GSK plc’s respiratory syncytial virus (RSV) vaccines for older adults appear headed for easy US Food and Drug Administration approval, but their use in younger seniors – those 60 to 64 – may be limited by the Centers for Disease Control and Prevention following the most recent Advisory Committee on Immunization Practices on the products.
After ACIP Gambit, Pfizer, GSK Take RSV Vaccines To US FDA Adcomm
The Vaccines and Related Biological Products Advisory Committee is scheduled to consider the RSV vaccine candidates on 28 February and 1 March.
More from Vaccines
More from Pink Sheet
• By
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
• By
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
• By
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.